Results 91 to 100 of about 1,131 (155)

Corrigendum to "Selpercatinib in Chinese patients with <i>RET</i>-fusion-positive non-small-cell lung cancer: updated efficacy and safety analysis from the LIBRETTO-321 phase II trial". [PDF]

Ther Adv Med Oncol
europepmc   +1 more source

LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive (RET+) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC. [PDF]

Lung Cancer (Auckl)
Lee ATM, Ou SI.
europepmc   +1 more source

Long-term safety of selpercatinib for Rearranged during transfection (RET)-activated advanced solid tumors in LIBRETTO-001: differing patterns of adverse events over time. [PDF]

Oncologist
Raez LE, Massey AC, Barker SS, Peterson PM, Liming K, Pennell NA.   +5 more
europepmc   +1 more source

Assessing tolerability with the Functional Assessment of Cancer Therapy item GP5: psychometric evidence from LIBRETTO-531, a phase 3 trial of selpercatinib in medullary thyroid cancer. [PDF]

J Patient Rep Outcomes
Regnault A, Bunod L, Loubert A, Brose MS, Hess LM, Maeda P, Lin Y, Speck RM, Gilligan AM, Payakachat N.   +9 more
europepmc   +1 more source

Selpercatinib in <i>RET</i> Fusion-Positive Non-Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial. [PDF]

J Clin Oncol
Gautschi O, Park K, Solomon BJ, Tomasini P, Loong HH, De Braud F, Goto K, Peterson P, Barker S, Liming K, Oxnard GR, Frimodt-Moller B, Drilon A.   +12 more
europepmc   +1 more source

Erratum: Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial. [PDF]

J Clin Oncol, 2023
europepmc   +1 more source

Round-Robin Comparison of RET Rearrangement Detection in ctDNA: A Novel Method for Limited Clinical Samples. [PDF]

Clin Cancer Res
Paweletz CP, Urvalek A, Ha M, Garg K, Bence Lin A, Szpurka AM, Sireci A, Oxnard GR, Janne PA.   +8 more
europepmc   +1 more source

Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001. [PDF]

J Clin Oncol
Wirth LJ, Brose MS, Subbiah V, Worden F, Solomon B, Robinson B, Hadoux J, Tomasini P, Weiler D, Deschler-Baier B, Tan DSW, Maeda P, Lin Y, Singh R, Bayt T, Drilon A, Cassier PA.   +16 more
europepmc   +1 more source

Non-Small-Cell Lung Cancers (NSCLCs) Harboring RET Gene Fusion, from Their Discovery to the Advent of New Selective Potent RET Inhibitors: "Shadows and Fogs". [PDF]

Cancers (Basel)
Spitaleri G, Trillo Aliaga P, Attili I, Del Signore E, Corvaja C, Pellizzari G, Katrini J, Passaro A, de Marinis F.   +8 more
europepmc   +1 more source

RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future. [PDF]

Drugs
Chen MF, Repetto M, Wilhelm C, Drilon A.
europepmc   +1 more source